23andMe, Inc. announced on 4 February it is becoming a publicly traded company through a merger with a special purpose acquisitions company (SPAC) backed by Virgin Group founder Sir Richard Branson in a deal that values the genetic-testing company at $3.5bn, including debt.
As part of the agreement with the blank check firm VG Acquisition Corp